EGFR and non-small cell lung carcinoma: This prompted us to explore a chemotherapy‐free regimen of atezolizumab plus bevacizumab, aiming to provide an additional, and potentially less toxic, option for previously treated patients with EGFR mutation‐positive NSCLC.